share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股SEC公告 ·  2024/11/25 06:57

Moomoo AI 已提取核心訊息

At a Special Meeting held on November 22, 2024, Transcode Therapeutics' shareholders approved three key proposals. The meeting saw participation from 9,480,060 shares out of 17,265,658 eligible voting shares.Shareholders approved the issuance of 10 million shares of Common Stock and warrants for 500,000 shares to ThinkEquity LLC in a best efforts public offering. Additionally, they authorized a reverse stock split at a ratio between 1-for-10 and 1-for-40, with timing to be determined by the Board of Directors.The voting results showed strong support across all proposals, with the Reverse Stock Split Proposal receiving 7,271,421 votes in favor and the Adjournment Proposal gaining 7,738,700 positive votes. No adjournment was necessary as sufficient votes were secured for all proposals.
At a Special Meeting held on November 22, 2024, Transcode Therapeutics' shareholders approved three key proposals. The meeting saw participation from 9,480,060 shares out of 17,265,658 eligible voting shares.Shareholders approved the issuance of 10 million shares of Common Stock and warrants for 500,000 shares to ThinkEquity LLC in a best efforts public offering. Additionally, they authorized a reverse stock split at a ratio between 1-for-10 and 1-for-40, with timing to be determined by the Board of Directors.The voting results showed strong support across all proposals, with the Reverse Stock Split Proposal receiving 7,271,421 votes in favor and the Adjournment Proposal gaining 7,738,700 positive votes. No adjournment was necessary as sufficient votes were secured for all proposals.
在2024年11月22日召開的特別會議上，Transcode Therapeutics的股東批准了三個關鍵提案。此次會議共計參與了9,480,060股中的17,265,658股有投票權股份。股東批准向ThinkEquity LLC發行1000萬股普通股和500,000股的Warrants，作爲最佳努力的公開募股。此外，他們授權進行反向拆股，比例在1:10到1:40之間，具體時間由董事會決定。投票結果顯示所有提案都獲得了強烈的壓力位，反向拆股提案獲得了7,271,421票支持，而延期提案則獲得了7,738,700票支持。由於所有提案都獲得了足夠的票數，因此不需要延期。
在2024年11月22日召開的特別會議上，Transcode Therapeutics的股東批准了三個關鍵提案。此次會議共計參與了9,480,060股中的17,265,658股有投票權股份。股東批准向ThinkEquity LLC發行1000萬股普通股和500,000股的Warrants，作爲最佳努力的公開募股。此外，他們授權進行反向拆股，比例在1:10到1:40之間，具體時間由董事會決定。投票結果顯示所有提案都獲得了強烈的壓力位，反向拆股提案獲得了7,271,421票支持，而延期提案則獲得了7,738,700票支持。由於所有提案都獲得了足夠的票數，因此不需要延期。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股集體大漲！2025年中國資產前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家機構唱好中國資產。 $阿里巴巴 (BABA.US)$ 、 $京東 (JD.US)$ 、 $富途控股 (FUTU.US)$ 等中概股價格飆升，市場情緒火熱。 🎙️討論： Deepseek 展开
    中國股票的瘋狂反彈暫停了？華爾街仍然對熱門股下注